Exome Asset Management LLC Sells 659,200 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)

Exome Asset Management LLC lessened its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) by 58.5% in the third quarter, Holdings Channel.com reports. The institutional investor owned 468,499 shares of the company’s stock after selling 659,200 shares during the period. Exome Asset Management LLC’s holdings in Gossamer Bio were worth $462,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sequoia Financial Advisors LLC grew its stake in Gossamer Bio by 27.2% during the second quarter. Sequoia Financial Advisors LLC now owns 93,500 shares of the company’s stock worth $84,000 after purchasing an additional 20,000 shares during the period. Financial Advocates Investment Management boosted its holdings in shares of Gossamer Bio by 57.5% during the 2nd quarter. Financial Advocates Investment Management now owns 106,850 shares of the company’s stock worth $96,000 after buying an additional 39,000 shares in the last quarter. TD Asset Management Inc grew its position in shares of Gossamer Bio by 51.9% during the 2nd quarter. TD Asset Management Inc now owns 641,498 shares of the company’s stock worth $578,000 after buying an additional 219,238 shares during the period. Acadian Asset Management LLC increased its stake in shares of Gossamer Bio by 31.3% in the 2nd quarter. Acadian Asset Management LLC now owns 3,592,765 shares of the company’s stock valued at $3,235,000 after acquiring an additional 856,380 shares in the last quarter. Finally, Choreo LLC acquired a new position in shares of Gossamer Bio during the 2nd quarter valued at $46,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Gossamer Bio in a report on Monday, November 11th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $9.20.

Gossamer Bio Price Performance

Shares of NASDAQ:GOSS opened at $0.93 on Friday. The firm has a market capitalization of $210.74 million, a price-to-earnings ratio of -2.91 and a beta of 1.85. The stock’s 50 day moving average is $0.84 and its 200-day moving average is $0.87. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 3.64. Gossamer Bio, Inc. has a twelve month low of $0.50 and a twelve month high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. The business had revenue of $9.48 million during the quarter, compared to the consensus estimate of $4.52 million. Sell-side analysts forecast that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.